Inventor · disambiguated record
Daniel J. Freeman
Also filed as: FREEMAN DANIEL · FREEMAN DANIEL J
15 granted patents·10 pending applications·96 citations·filing 1995–2023
91Inventor score
Top patents by PatentIndex Score
25 records- 0185US8771695B2Antibodies directed to HER-3 and uses thereofROTHE MIKE·Filed 2010·Granted Jul 8, 2014·8 cites·20 claims
- 0285US7981605B2Epidermal growth factor receptor mutationsAMGEN INC·Filed 2006·Granted Jul 19, 2011·7 cites·2 claims
- 0382US9101760B2Material and methods for treating or preventing HER-3 associated diseasesHETTMANN THORE·Filed 2010·Granted Aug 11, 2015·7 cites·36 claims
- 0481US12497666B2Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2023·Granted Dec 16, 2025·0 cites·8 claims
- 0579US6022737AFormulations for non-viral in vivo transfection in the lungsAMGEN INC·Filed 1995·Granted Feb 8, 2000·63 cites·8 claims
- 0678US9988462B2Material and methods for treating or preventing HER-3 associated diseasesDAIICHI SANKYO EUROPE GMBH·Filed 2016·Granted Jun 5, 2018·2 cites·31 claims
- 0778US9803025B2Material and methods for treating or preventing HER-3 associated diseasesDAIICHI SANKYO EUROPE GMBH·Filed 2013·Granted Oct 31, 2017·3 cites·38 claims
- 0874US7985559B2Methods of selecting epidermal growth factor receptor (EGFR) binding agentsAMGEN INC·Filed 2008·Granted Jul 26, 2011·5 cites·13 claims
- 0972US11840736B2Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2019·Granted Dec 12, 2023·0 cites·14 claims
- 1069US11873344B2Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2019·Granted Jan 16, 2024·0 cites·12 claims
- 1168US11155876B2K-ras mutations and anti-EGFr antibody therapyAMGEN INC·Filed 2018·Granted Oct 26, 2021·0 cites·1 claims
- 1267US12139549B2Material and methods for treating or preventing HER-3 associated diseasesDAIICHI SANKYO EUROPE GMBH·Filed 2017·Granted Nov 12, 2024·0 cites·20 claims
- 1366US2008293055A1K-ras mutations and anti-EGFr antibody therapyFREEMAN DANIEL·Filed 2008·Application pending·0 cites
- 1465US8546107B2Epidermal growth factor receptor mutationsFREEMAN DANIEL J·Filed 2011·Granted Oct 1, 2013·1 cites·7 claims
- 1564US10030270B2K-ras mutations and anti-EGFr antibody therapyFREEMAN DANIEL·Filed 2012·Granted Jul 24, 2018·0 cites·3 claims
- 1662US2024075160A1Combination therapies for treatment of cancerMEDIMMUNE LLC·Filed 2023·Application pending·0 cites
- 1757US2015152508A1Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2014·Application pending·0 cites
- 1856US2015147326A1Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2014·Application pending·0 cites
- 1955US2023322928A1Treatment methods using ctla-4 and pd-1 bispecific antibodiesMEDIMMUNE LLC·Filed 2023·Application pending·0 cites
- 2050US2017166973A1Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2016·Application pending·0 cites
- 2150US2017166654A1Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2016·Application pending·0 cites
- 2249US2020199567A1Methods for selection and expansion of t cells expressing pd-1MEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 2347US9097729B2Methods of selecting epidermal growth factor receptor (EGFr) binding agentsFREEMAN DANIEL J·Filed 2011·Granted Aug 4, 2015·0 cites·16 claims
- 2441US2022211847A1Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancerMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 2536US2012156130A1Use of her3 binding agents in prostate treatmentHETTMANN THORE·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel J. Freeman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →